Metabolic Syndrome XNCT02151227
Magnesium and Metabolic Syndrome: A Dose-response Meta-analysis
An observational study of Metabolic Syndrome X and Insulin Resistance Syndrome X, run by The Catholic University of Korea at 1 site in South Korea.
Trial summary
Magnesium is an essential mineral found in many foods; rich sources include whole grains, green leafy vegetables, coffee, and legumes. Magnesium is a critical cofactor in >300 enzymatic reactions, including those related to energy metabolism. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Syndrome X, Insulin Resistance Syndrome X, Metabolic Cardiovascular Syndrome
- How many people
- 12 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jun 2014to Dec 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult population: 18 years old and older
Who may be able to join
- Dietary studies in humans 18 years old and older
- Randomized controlled study, Cohort study, Nested case-control study, Case-control study, Cross-sectional study
- The exposure of interest is magnesium intake (mg/day) or serum magnesium concentration(mmol/L, mg/dL)
Who cannot join
- Non-human studies
- Authors did not make serum magnesium concentration measurement;
- The outcome values can not be used for meta-analysis
- Duplicated articles.
- Studies are not published as full reports, such as conference abstracts and letters to editors
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Association of Dietary Magnesium Intake and Circulating Magnesium Concentration With Metabolic Syndrome: A Dose-response Meta-analysis
Magnesium is an essential mineral found in many foods; rich sources include whole grains, green leafy vegetables, coffee, and legumes. Magnesium is a critical cofactor in >300 enzymatic reactions, including those related to energy metabolism. Reduced magnesium intake and serum concentrations have been detected, both cross-sectionally and prospectively,in type 2 diabetes and insulin resistance, hypertension, dyslipidemia, and cardiovascular diseases.
Different studies have reported inadequate magnesium intake and low serum magnesium concentrations may correlated also with metabolic syndrome, defined as a cluster of metabolic disorders including obesity, hypertension, dyslipidemia and impaired glucose tolerance or diabetes mellitus. Previous studies on this subject, however, reported contradicting results. Some investigations reported inadequate magnesium intake and low serum magnesium concentrations while others did not.
To our knowledge, the epidemiological evidence on the relation between dietary magnesium intake and risk of metabolic syndrome has not yet been summarized.Therefore, the investigators will perform a systematic review and dose-response meta-analysis to assess the association between dietary and circulating magnesium level and risk of metabolic syndrome.
Read the detailed description
Background: Increasing evidence has suggested inadequate magnesium intake and low serum magnesium concentrations may correlated with metabolic syndrome. However, whether or not dietary or circulating magnesium at usual intakes or concentrations influences risk of metabolic syndrome is inconsistent
Objective:To our knowledge, the epidemiological evidence on the relation between dietary magnesium intake and risk of metabolic syndrome has not yet been summarized.Therefore, to improve evidence-based guidance for dietary guidelines, the investigators will perform a systematic review and dose-response meta-analysis to assess the association between dietary and circulating magnesium level and risk of metabolic syndrome.
Design: The planning, conduct and reporting of the proposed meta-analyses will follow Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
Data search and screening: The PubMed, Cochrane CENTRAL, and EMBASE databases via Elsevier will be searched using appropriate search terms.
Study selection: Published articles will be included: Randomized, controlled studies, case-control studies, cross-sectional studies and cohort studies. All studies enrolled adults (age 18 years) and reported metabolic syndrome as the outcome of interest and magnesium intake or serum magnesium concentration as a risk factor or intervention. They reported adjusted risk ratios, including odds ratios, relative risks, hazard ratios with 95% confidence intervals (CIs), or they reported sufficient data to calculate these values for 3 or more quantitative categories of dietary magnesium intake levels. They reported risk ratios with metabolic syndrome criteria according to the National Cholesterol Education Panel (NCEP), modified NCEP, American Heart Association/National Heart Lung and Blood Institute , and harmonized definition . The investigators selected articles written in English that were published in their entirety.
Data extraction: Titles and/or abstracts of studies retrieved using the search strategy will be screened independently by two review investigators to identify studies that potentially meet the inclusion criteria outlined above. The full text of these potentially eligible studies will be retrieved and independently assessed for eligibility by two investigators with disagreements being resolved by consensus. Data will be extracted from multivariate-adjusted models.
Extracted information will included: first author's surname, publication year, name of the cohort study, study location (nation), years of follow-up (in case of cohort study design), sex, age, sample size (prevalence of metabolic syndrome and total number of participants), dietary magnesium intake(mg/day), serum magnesium concentration, covariates adjusted for in the multivariable analysis, and risk ratios with their 95% confidence intervals for each category of dietary magnesium intake and serum magnesium concentrations. The investigators will extract risk ratios that reflect the greatest degree of adjustment for potential confounders. The study investigator will assess the risk of bias in included studies using a tool for assessing the risk of bias for nonrandomized studies (RoBANs) which contain the following eight domains: comparability of groups, selection of participants, confounding variables, measurement of exposure, blinding of outcome assessment, adequacy of outcome assessment, incomplete outcome data and selective outcome reporting.
Domains of RoBANs have the following characteristics:
Comparability of groups: Selection bias caused by the inadequate selection of comparable groups.
Selection of participants: Selection bias caused by the inadequate selection of participants.
Measurement of exposure: Performance bias caused by the inadequate confirmation and consideration of confounding variable.
Blinding of outcome assessments: Detection bias caused by the inadequate blinding of outcome assessments.
Incomplete outcome data: Attrition bias caused by the inadequate handling of incomplete outcome data.
Selective outcome reporting: Reporting bias caused by the selective reporting of outcome.
Adequacy of outcome assessments: Performance bias caused by the inadequate confirmation of outcomes.
RoBANS was developed to be used for the assessment of all study designs except for randomized controlled studies. RoBANS includes criteria for judging the risk of bias for each domain. Any discrepancies will be checked with the study investigator. A final copy of the form from each trial will be checked with the appropriate trial investigator for verification.
Outcomes: The investigators will perform a two stage random-effects dose-risk meta-analysis to examine a linear dose-response relationship between dose of magnesium intake and metabolic syndrome using a generalized least-squares method taking into account random effects. This method constructs a covariance estimate for dose-specific log relative risks (RRs) within each study and then estimates the dose-response relation, accounting for between- and within-study variation. Reported hazard ratios and odds ratios were assumed to approximate RRs.
For the dose-response meta-analysis, The investigators will generalized least-squares regression (GLST), which take into account the correlation between estimates for different expose level, to compute study-specific slopes. This method requires that the number of cases and controls (or person-years) and the RR with its variance estimate for at least three quantitative exposure categories were known. For studies that dose not provide this information, the investigators will estimate the dose-response slopes using variance-weighted least-squares regression (VWLS). Both the methods (GLST and VWLS) required median or mean intake for each category of intake level. For studies that report the concentrations as ranges of magnesium intake only, the investigators will estimate the midpoint in each category by calculating the average of the lower and upper bound. If the upper boundary for the highest category is not provided, the investigators will assume that the boundary has the same amplitude as the adjacent category. When the lowest category is open-ended, the investigators will set the lower boundary to the same amplitude as the adjacent category. In the case of different categorizations of magnesium intake and serum concentrations across studies, the investigators will choose the lowest level as the reference category. Dose responses of dietary magnesium intake will be standardized based on unweighted median differences between the highest and lowest quartile category medians across all studies.
For the meta-analysis, the statistical heterogeneity between the studies will be assessed using the Q and I-squared statistics. For the Q statistic, heterogeneity was considered present if p < 0.1. The investigators will define low, moderate and high heterogeneity as I-squared values of 25%, 50% and 75%, respectively. Publication bias will be evaluated using Begg's test. In the presence of publication bias, the P values for Begg's test are less than 0.05. The investigators will conduct sensitivity analyses to evaluate potential sources of heterogeneity in the analyses. The investigators will conduct subgroup meta-analyses according to the study design (cross-sectional study, cohort cohort or nested case-control study), study quality, definition of metabolic syndrome, gender, age, and geographic area of the study
- Conditions
- Metabolic Syndrome X, Insulin Resistance Syndrome X, Metabolic Cardiovascular Syndrome, Dysmetabolic Syndrome X
- Keywords
- Meta-Analysis, Metabolic Syndrome, Magnesium, Dose Response Effect, Systematic Review
- Medical subject headings
- Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| magnesium intake categories | comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolic syndrome risk ratios (Odds ratio, Relative risk, Hazard ratio)
Measured: Baseline
Secondary outcomes (1)
Serum magnesium concentration (mg/dL, mmol/L)
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2014 (estimated)
- Study startJun 2014
- Primary completionSep 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Metabolic Syndrome XStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Catholic University of Korea
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ju Sang-yhun, The Catholic University of Korea
- Investigators
- Sang-yhun Ju, Ph.D., Principal investigator, Department of Family Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02151227
- Sponsor's protocol ID
- SC14EISI0086
- Status last verified
- Dec 2014
- First submitted
- 28 May 2014
- Last updated
- 30 Dec 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Ju SY, Choi WS, Ock SM, Kim CM, Kim DH. Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression. Nutrients. 2014 Dec 22;6(12):6005-19. doi: 10.3390/nu6126005.
PubMed 25533010La SA, Lee JY, Kim DH, Song EL, Park JH, Ju SY. Low Magnesium Levels in Adults with Metabolic Syndrome: a Meta-Analysis. Biol Trace Elem Res. 2016 Mar;170(1):33-42. doi: 10.1007/s12011-015-0446-9. Epub 2015 Jul 26.
PubMed 26208810
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Dietary Magnesium Intake and Circulating Magnesium Concentration With Metabolic Syndrome: A Dose-response Meta-analysis
- ClinicalTrials.gov ID
- NCT02151227
- Acronym / sponsor ID
- SC14EISI0086
- Conditions
- Metabolic Syndrome X, Insulin Resistance Syndrome X, Metabolic Cardiovascular Syndrome, Dysmetabolic Syndrome X
- Keywords
- Meta-Analysis, Metabolic Syndrome, Magnesium, Dose Response Effect, Systematic Review
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- The Catholic University of KoreaUniversity, hospital or other
- Study start
- Jun 2014
- Primary completion
- Sep 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 30 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Magnesium is an essential mineral found in many foods; rich sources include whole grains, green leafy vegetables, coffee, and legumes. Magnesium is a critical cofactor in >300 enzymatic reactions, including those related to energy metabolism. Reduced magnesium intake and serum concentrations have been detected, both cross-sectionally and prospectively,in type 2 diabetes and insulin resistance, hypertension, dyslipidemia, and cardiovascular diseases.
Different studies have reported inadequate magnesium intake and low serum magnesium concentrations may correlated also with metabolic syndrome, defined as a cluster of metabolic disorders including obesity, hypertension, dyslipidemia and impaired glucose tolerance or diabetes mellitus. Previous studies on this subject, however, reported contradicting results. Some investigations reported inadequate magnesium intake and low serum magnesium concentrations while others did not.
To our knowledge, the epidemiological evidence on the relation between dietary magnesium intake and risk of metabolic syndrome has not yet been summarized.Therefore, the investigators will perform a systematic review and dose-response meta-analysis to assess the association between dietary and circulating magnesium level and risk of metabolic syndrome.
Detailed description
Background: Increasing evidence has suggested inadequate magnesium intake and low serum magnesium concentrations may correlated with metabolic syndrome. However, whether or not dietary or circulating magnesium at usual intakes or concentrations influences risk of metabolic syndrome is inconsistent
Objective:To our knowledge, the epidemiological evidence on the relation between dietary magnesium intake and risk of metabolic syndrome has not yet been summarized.Therefore, to improve evidence-based guidance for dietary guidelines, the investigators will perform a systematic review and dose-response meta-analysis to assess the association between dietary and circulating magnesium level and risk of metabolic syndrome.
Design: The planning, conduct and reporting of the proposed meta-analyses will follow Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
Data search and screening: The PubMed, Cochrane CENTRAL, and EMBASE databases via Elsevier will be searched using appropriate search terms.
Study selection: Published articles will be included: Randomized, controlled studies, case-control studies, cross-sectional studies and cohort studies. All studies enrolled adults (age 18 years) and reported metabolic syndrome as the outcome of interest and magnesium intake or serum magnesium concentration as a risk factor or intervention. They reported adjusted risk ratios, including odds ratios, relative risks, hazard ratios with 95% confidence intervals (CIs), or they reported sufficient data to calculate these values for 3 or more quantitative categories of dietary magnesium intake levels. They reported risk ratios with metabolic syndrome criteria according to the National Cholesterol Education Panel (NCEP), modified NCEP, American Heart Association/National Heart Lung and Blood Institute , and harmonized definition . The investigators selected articles written in English that were published in their entirety.
Data extraction: Titles and/or abstracts of studies retrieved using the search strategy will be screened independently by two review investigators to identify studies that potentially meet the inclusion criteria outlined above. The full text of these potentially eligible studies will be retrieved and independently assessed for eligibility by two investigators with disagreements being resolved by consensus. Data will be extracted from multivariate-adjusted models.
Extracted information will included: first author's surname, publication year, name of the cohort study, study location (nation), years of follow-up (in case of cohort study design), sex, age, sample size (prevalence of metabolic syndrome and total number of participants), dietary magnesium intake(mg/day), serum magnesium concentration, covariates adjusted for in the multivariable analysis, and risk ratios with their 95% confidence intervals for each category of dietary magnesium intake and serum magnesium concentrations. The investigators will extract risk ratios that reflect the greatest degree of adjustment for potential confounders. The study investigator will assess the risk of bias in included studies using a tool for assessing the risk of bias for nonrandomized studies (RoBANs) which contain the following eight domains: comparability of groups, selection of participants, confounding variables, measurement of exposure, blinding of outcome assessment, adequacy of outcome assessment, incomplete outcome data and selective outcome reporting.
Domains of RoBANs have the following characteristics:
Comparability of groups: Selection bias caused by the inadequate selection of comparable groups.
Selection of participants: Selection bias caused by the inadequate selection of participants.
Measurement of exposure: Performance bias caused by the inadequate confirmation and consideration of confounding variable.
Blinding of outcome assessments: Detection bias caused by the inadequate blinding of outcome assessments.
Incomplete outcome data: Attrition bias caused by the inadequate handling of incomplete outcome data.
Selective outcome reporting: Reporting bias caused by the selective reporting of outcome.
Adequacy of outcome assessments: Performance bias caused by the inadequate confirmation of outcomes.
RoBANS was developed to be used for the assessment of all study designs except for randomized controlled studies. RoBANS includes criteria for judging the risk of bias for each domain. Any discrepancies will be checked with the study investigator. A final copy of the form from each trial will be checked with the appropriate trial investigator for verification.
Outcomes: The investigators will perform a two stage random-effects dose-risk meta-analysis to examine a linear dose-response relationship between dose of magnesium intake and metabolic syndrome using a generalized least-squares method taking into account random effects. This method constructs a covariance estimate for dose-specific log relative risks (RRs) within each study and then estimates the dose-response relation, accounting for between- and within-study variation. Reported hazard ratios and odds ratios were assumed to approximate RRs.
For the dose-response meta-analysis, The investigators will generalized least-squares regression (GLST), which take into account the correlation between estimates for different expose level, to compute study-specific slopes. This method requires that the number of cases and controls (or person-years) and the RR with its variance estimate for at least three quantitative exposure categories were known. For studies that dose not provide this information, the investigators will estimate the dose-response slopes using variance-weighted least-squares regression (VWLS). Both the methods (GLST and VWLS) required median or mean intake for each category of intake level. For studies that report the concentrations as ranges of magnesium intake only, the investigators will estimate the midpoint in each category by calculating the average of the lower and upper bound. If the upper boundary for the highest category is not provided, the investigators will assume that the boundary has the same amplitude as the adjacent category. When the lowest category is open-ended, the investigators will set the lower boundary to the same amplitude as the adjacent category. In the case of different categorizations of magnesium intake and serum concentrations across studies, the investigators will choose the lowest level as the reference category. Dose responses of dietary magnesium intake will be standardized based on unweighted median differences between the highest and lowest quartile category medians across all studies.
For the meta-analysis, the statistical heterogeneity between the studies will be assessed using the Q and I-squared statistics. For the Q statistic, heterogeneity was considered present if p < 0.1. The investigators will define low, moderate and high heterogeneity as I-squared values of 25%, 50% and 75%, respectively. Publication bias will be evaluated using Begg's test. In the presence of publication bias, the P values for Begg's test are less than 0.05. The investigators will conduct sensitivity analyses to evaluate potential sources of heterogeneity in the analyses. The investigators will conduct subgroup meta-analyses according to the study design (cross-sectional study, cohort cohort or nested case-control study), study quality, definition of metabolic syndrome, gender, age, and geographic area of the study
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| magnesium intake categories | – | –comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult population: 18 years old and older
Key inclusion criteria (3 listed)
- Dietary studies in humans 18 years old and older
- Randomized controlled study, Cohort study, Nested case-control study, Case-control study, Cross-sectional study
- The exposure of interest is magnesium intake (mg/day) or serum magnesium concentration(mmol/L, mg/dL)
Key exclusion criteria (5 listed)
- Non-human studies
- Authors did not make serum magnesium concentration measurement;
- The outcome values can not be used for meta-analysis
- Duplicated articles.
- Studies are not published as full reports, such as conference abstracts and letters to editors
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Metabolic syndrome risk ratios (Odds ratio, Relative risk, Hazard ratio)
Time frame: Baseline
1 secondary outcome
Serum magnesium concentration (mg/dL, mmol/L)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2014.
- Results publication: PubMed 25533010Ju SY, Choi WS, Ock SM, Kim CM, Kim DH. Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression. Nutrients. 2014 Dec 22;6(12):6005-19. doi: 10.3390/nu6126005.
- Derived from this study: PubMed 26208810La SA, Lee JY, Kim DH, Song EL, Park JH, Ju SY. Low Magnesium Levels in Adults with Metabolic Syndrome: a Meta-Analysis. Biol Trace Elem Res. 2016 Mar;170(1):33-42. doi: 10.1007/s12011-015-0446-9. Epub 2015 Jul 26.
- pubmedLink provided by the sponsor.
Related trials for Metabolic Syndrome X
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
RecruitingObservational study
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Inherited Disease, Rare Diseases
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingPhase 1/2
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
Obesity, Metabolic Syndrome
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sang-yhun Ju, Ph.D. principal investigator
Department of Family Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Metabolic Syndrome X and Insulin Resistance Syndrome X, run by The Catholic University of Korea at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolic syndrome risk ratios (Odds ratio, Relative risk, Hazard ratio) (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02151227, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2014.